Malaria is the most devastating parasitic disease worldwide. Artemisinin is the only drug that can cure malaria that is resistant to quinine-derived drugs. After the commercial extraction of artemisinin from Artemisia annua, the recovery of dihydroartemisinic acid (DHAA) from artemisinin extraction by-product has the potential to increase artemisinin commercial yield. Here we describe the development and optimization of an ultrasound-assisted alkaline procedure for the extraction of DHAA from artemisinin production waste using response surface methodology. Our results using this methodology established that NaOH at 0.36%, extraction time of 67.96 min, liquid-solid ratio of 5.89, and ultrasonic power of 83.9 W were the optimal conditions to extract DHAA from artemisinin production waste. Under these optimal conditions, we achieved a DHAA yield of 2.7%. Finally, we conducted a validation experiment, and the results confirmed the prediction generated by the regression model developed in this study. This work provides a novel way to increase the production of artemisinin per cultivated area and to reduce artemisinin production costs by recycling its commercial waste to obtain DHAA, an immediate precursor of artemisinin. The use of this technology may reduce the costs of artemisinin-based antimalarial medicines.Key words dihydroartemisinic acid; ultrasound-assisted extraction; response surface; Artemisia annua L.; alkaline extraction; acid precipitation Malaria is one of the world's most important parasitic diseases, affects approximately 300-500 million people worldwide, and causes more than one million deaths per year (WHO: World Malaria Report 2015, http://www.who.int/ malaria/publications/world-malaria-report-2015/report/en/).
1)Artemisia annua, L. is currently the only commercial source of artemisinin, the raw material for the production of artemisinin combination therapies (ACTs). ACTs are the frontline and life-saving medicine to treat malaria where Plasmodium falciparum is endemic and resistant to quinine-derived medicines. ACTs cost between US$ 1.0 and 3.50 per treatment and can be required many times a year by people living in malaria-endemic areas. However, at the current cost ACTs are unaffordable for people living in economically-stricken countries, and who need it the most.2) Thus, it is of paramount importance and urgency to reduce the production costs of artemisinin-derived antimalarial medicines. One way to achieve this goal is by increasing artemisinin yield per cultivated area and by improving the extraction efficiency of artemisinin and its related compounds from leaves of A. annua. Although the production of one of the artemisinin precursors (artemisinic acid) in genetically-engineered yeast was developed, no economically feasible artemisinin product is yet available from this technology, and its predicted cost is higher than current market prices for plant-based artemisinin. The production of artemisinin in planta surpasses what can be achieved by microorganisms engineered to produce the precurs...